Authors
Grace A McComsey, Sergio Lupo, David Parks, Monica Coronado Poggio, Joseph De Wet, Lesley P Kahl, Kostas Angelis, Brian Wynne, Kati Vandermeulen, Martin Gartland, Michael Cupo, Michael Aboud, 202094 Sub-Study Investigators
Publication date
2018/2/20
Journal
Aids
Volume
32
Issue
4
Pages
477-485
Publisher
LWW
Description
Objective:
Bone mineral density (BMD) loss, a risk factor for osteoporosis, has been attributed to HIV infection and antiretroviral therapy (ART), including regimens containing tenofovir disoproxil fumarate.
Design:
Study 202094 is an open-label, parallel-group, sub-study of the phase III SWORD-1 and SWORD-2 studies (ClinicalTrials. gov identifier, NCT02478632).
Methods:
HIV-1-infected adults with HIV-1 RNA less than 50 copies/ml who received ART containing tenofovir disoproxil fumarate for at least 6 months were randomized to receive dolutegravir with rilpivirine or continue current ART regimen. Total hip and lumbar spine BMD were measured by dual-energy X-ray absorptiometry (DXA) scans. The primary endpoint was percentage change from baseline in total hip BMD.
Results:
DXA scans were evaluable for 81 participants at baseline and Week 48. Percentage increase in total hip BMD was significantly greater …
Scholar articles
GA McComsey, S Lupo, D Parks, MC Poggio, J De Wet… - Aids, 2018